---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-016805"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T15:00:42.932310+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances

## Summary
- Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.
- Cash, equivalents, and marketable securities $158.9M at Dec 31, 2025; extended runway into H1 2028 after $50M Jan 2026 financing.
- Ryan Maynard appointed CFO in Feb 2026, bringing over 25 years of biopharma finance experience.
- Lead candidate FHD-909 Phase 1 dose-escalation on track; collaboration with Lilly advancing.
- Selective CBP and EP300 degrader programs on track for IND-enabling studies in 2026.

## SEC filing metadata
- accession: 0001628280-26-016805
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828026016805/0001628280-26-016805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828026016805/fhtx-20260311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-016805
- JSON: https://secwatch.observer/filing/0001628280-26-016805.json
- Plain text: https://secwatch.observer/filing/0001628280-26-016805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.